The Pancreatic Cancer Action Network has named four new members to the organization's Medical Advisory Board. The newest advisors are leading clinicians in the field of pancreatic cancer: Joseph M. Herman, MD, MSc, Johns Hopkins University; George A. Fisher Jr., MD, PhD, Stanford University; James Farrell, MD, Yale University; and Philip Agop Philip, MD, PhD, Karmanos Cancer Center.
"I am pleased to welcome these distinguished leaders to our Medical Advisory Board. They bring a great wealth of expertise to the organization and their active participation will further strengthen our programs to support pancreatic cancer patients," stated Julie Fleshman, President and CEO of the Pancreatic Cancer Action Network. "The role of the Medical Advisory Board is essential as the Pancreatic Cancer Action Network work to double the survival for pancreatic cancer by 2020."
The Medical Advisory Board includes clinicians who specialize in the care of people with pancreatic cancer. The board advises the organization on specific medical and clinical aspects of pancreatic cancer as it relates to our programs. Rounding out the Medical Advisory Board is: Jordan Berlin, MD, Chair, Vanderbilt-Ingram Cancer Center; Marcia Canto, MD, Johns Hopkins University; Christopher Crane, MD, MD Anderson Cancer Center; Jason Fleming, MD, MD Anderson Cancer Center; Jane Hanna, RN, OCN, Georgetown University Hospital; Mokenge Malafa, MD, Moffitt Cancer Center; Eileen O'Reilly, MD, Memorial Sloan-Kettering Cancer Center; Maria Petzel, RD, CSO, LD, CNSC, MD Anderson Cancer Center; Vincent Picozzi, MD, Virginia Mason Medical Center; Mark Pochapin, MD, New York University and Mark Talamonti, MD, NorthShore University HealthSystem.
To learn more about the Pancreatic Cancer Action Network's Medical Advisory Board, click here.
About the Pancreatic Cancer Action Network
The Pancreatic Cancer Action Network is the national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organization is leading the way to increase the survival rate for people diagnosed with this devastating disease through a bold initiative—The Vision of Progress: Double the Pancreatic Cancer Survival Rate by 2020. Together, we can know, fight and end pancreatic cancer by intensifying our efforts to heighten awareness, raise funds for comprehensive private research, and advocate for dedicated federal research to advance early diagnostics, better treatments and increase chances of survival.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.